In collaboration with the Sorbonne University, Ksilink used both patient-derived and genome edited cellular models for desmin-related cardiomyopathy to analyze how the DESE439K...
As a member of the JUMP Cell Painting Consortium, Ksilink contributed to the perturbation of roughly 75% of the protein-coding genome in human U-2 OS cells, generating a rich...
In collaboration with the University of Luxembourg, Ksilink used a patient-derived cellular model for Parkinson’s Disease based on SNCA triplication and isogenic control mDA...
Since 2019, Ksilink has been part of the JUMP-Cell Painting Consortium, a collaboration between 10 pharmaceutical companies, six supporting technology companies, and two...
